Adial Pharmaceuticals (ADIL) Intangibles (2017 - 2026)
Adial Pharmaceuticals (ADIL) posted Intangibles of $2643.0 for Q1 2026, down 5.06% sequentially from $2784.0 in Q4 2025, and down 17.59% YoY from $3207.0 in Q1 2025.
Adial Pharmaceuticals (ADIL) Intangibles (2017 - 2026) Analysis & Trends
Adial Pharmaceuticals has reported Intangibles for 10 years, with the latest figure at $2643.0 in Q1 2026.
- Quarterly Intangibles fell 17.59% year-over-year to $2643.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2643.0 (down 17.59% YoY) and the FY2025 annual result came in at $2784.0, down 16.85% from the prior year.
- Intangibles slipped to $2643.0 in Q1 2026 per ADIL's latest filing, from $2784.0 in the prior quarter.
- Over five years, Intangibles peaked at $4900.0 in Q1 2022 and troughed at $2643.0 in Q1 2026.
- A 5-year average of $3771.6 and a median of $3772.0 in 2024 frame the typical range for Intangibles.
- The sharpest annual moves came in 2022 and 2026: Intangibles slipped 10.34% in 2022, then fell 17.59% in 2026.
- Over 5 years, Intangibles stood at $4477.0 in 2022, then slipped by 12.6% to $3913.0 in 2023, then decreased by 14.44% to $3348.0 in 2024, then slipped by 16.85% to $2784.0 in 2025, then fell by 5.06% to $2643.0 in 2026.
- According to Business Quant data, Intangibles over the past three periods registered $2643.0, $2784.0, and $2925.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 412.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.31 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 266.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 60.96 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 93.49 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Adial Pharmaceuticals | 29.02 Mn | 29.02 Mn | - | 3,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2,643.00 |
| Dec 31, 2025 | 2,784.00 |
| Sep 30, 2025 | 2,925.00 |
| Jun 30, 2025 | 3,066.00 |
| Mar 31, 2025 | 3,207.00 |
| Dec 31, 2024 | 3,348.00 |
| Sep 30, 2024 | 3,489.00 |
| Jun 30, 2024 | 3,631.00 |
| Mar 31, 2024 | 3,772.00 |
| Dec 31, 2023 | 3,913.00 |
| Sep 30, 2023 | 4,054.00 |
| Jun 30, 2023 | 4,195.00 |
| Mar 31, 2023 | 4,336.00 |
| Dec 31, 2022 | 4,477.00 |
| Sep 30, 2022 | 4,618.00 |
| Jun 30, 2022 | 4,759.00 |
| Mar 31, 2022 | 4,900.00 |
| Dec 31, 2021 | 5,041.00 |
| Sep 30, 2021 | 5,183.00 |
| Jun 30, 2021 | 5,324.00 |